

AMENDMENTS TO LB 239

Introduced by Harr

1           1. Strike the original sections and all amendments  
2 thereto and insert the following new sections:

3           Section 1. Section 28-405, Revised Statutes Supplement,  
4 2011, is amended to read:

5           28-405 The following are the schedules of controlled  
6 substances referred to in the Uniform Controlled Substances Act:

7           Schedule I

8           (a) Any of the following opiates, including their  
9 isomers, esters, ethers, salts, and salts of isomers, esters, and  
10 ethers, unless specifically excepted, whenever the existence of  
11 such isomers, esters, ethers, and salts is possible within the  
12 specific chemical designation:

13           (1) Acetylmethadol;

14           (2) Allylprodine;

15           (3) Alphacetylmethadol, except levo-alphacetylmethadol  
16 which is also known as levo-alpha-acetylmethadol, levomethadyl  
17 acetate, and LAAM;

18           (4) Alphameprodine;

19           (5) Alphamethadol;

20           (6) Benzethidine;

21           (7) Betacetylmethadol;

22           (8) Betameprodine;

23           (9) Betamethadol;

- 1 (10) Betaprodine;
- 2 (11) Clonitazene;
- 3 (12) Dextromoramide;
- 4 (13) Difenoquin;
- 5 (14) Diampromide;
- 6 (15) Diethylthiambutene;
- 7 (16) Dimenoxadol;
- 8 (17) Dimepheptanol;
- 9 (18) Dimethylthiambutene;
- 10 (19) Dioxaphetyl butyrate;
- 11 (20) Dipipanone;
- 12 (21) Ethylmethylthiambutene;
- 13 (22) Etonitazene;
- 14 (23) Etozeridine;
- 15 (24) Furethidine;
- 16 (25) Hydroxypethidine;
- 17 (26) Ketobemidone;
- 18 (27) Levomoramide;
- 19 (28) Levophenacymorphan;
- 20 (29) Morpheridine;
- 21 (30) Noracymethadol;
- 22 (31) Norlevorphanol;
- 23 (32) Normethadone;
- 24 (33) Norpipanone;
- 25 (34) Phenadoxone;
- 26 (35) Phenampromide;
- 27 (36) Phenomorphan;

- 1 (37) Phenoperidine;
- 2 (38) Piritramide;
- 3 (39) Proheptazine;
- 4 (40) Properidine;
- 5 (41) Propiram;
- 6 (42) Racemoramide;
- 7 (43) Trimeperidine;
- 8 (44) Alpha-methylfentanyl,  
9 N-(1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl) propionanilide,  
10 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine;
- 11 (45) Tilidine;
- 12 (46) 3-Methylfentanyl,  
13 N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide, its  
14 optical and geometric isomers, salts, and salts of isomers;
- 15 (47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its  
16 optical isomers, salts, and salts of isomers;
- 17 (48) PEPAP, 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine,  
18 its optical isomers, salts, and salts of isomers;
- 19 (49) Acetyl-alpha-methylfentanyl,  
20 N-(1-(1-methyl-2-phenethyl)-4-piperidinyl)-N-phenylacetamide, its  
21 optical isomers, salts, and salts of isomers;
- 22 (50) Alpha-methylthiofentanyl,  
23 N-(1-methyl-2-(2-thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide,  
24 its optical isomers, salts, and salts of isomers;
- 25 (51) Benzylfentanyl,  
26 N-(1-benzyl-4-piperidyl)-N-phenylpropanamide, its optical  
27 isomers, salts, and salts of isomers;

1                   (52)   Beta-hydroxyfentanyl,  
2 N-(1-(2-hydroxy-2-phenethyl)-4-piperidinyl)-N-phenylpropanamide,  
3 its optical isomers, salts, and salts of isomers;

4                   (53)       Beta-hydroxy-3-methylfentanyl,       (other       name:  
5 N-(1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide),  
6 its optical and geometric isomers, salts, and salts of isomers;

7                   (54)   3-methylthiofentanyl,  
8 N-(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide,  
9 its optical and geometric isomers, salts, and salts of isomers;

10                  (55)  
11 N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide  
12 (thenylfentanyl), its optical isomers, salts, and salts of isomers;

13                  (56)   Thiofentanyl,  
14 N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-propanamide,       its  
15 optical isomers, salts, and salts of isomers; and

16                  (57)   Para-fluorofentanyl,  
17 N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-piperidinyl)propanamide,  
18 its optical isomers, salts, and salts of isomers.

19                  (b) Any of the following opium derivatives, their salts,  
20 isomers, and salts of isomers, unless specifically excepted,  
21 whenever the existence of such salts, isomers, and salts of  
22 isomers is possible within the specific chemical designation:

- 23                  (1) Acetorphine;
- 24                  (2) Acetyldihydrocodeine;
- 25                  (3) Benzylmorphine;
- 26                  (4) Codeine methylbromide;
- 27                  (5) Codeine-N-Oxide;

- 1 (6) Cyprenorphine;
  - 2 (7) Desomorphine;
  - 3 (8) Dihydromorphine;
  - 4 (9) Drotebanol;
  - 5 (10) Etorphine, except hydrochloride salt;
  - 6 (11) Heroin;
  - 7 (12) Hydromorphenol;
  - 8 (13) Methyldesorphine;
  - 9 (14) Methyldihydromorphine;
  - 10 (15) Morphine methylbromide;
  - 11 (16) Morphine methylsulfonate;
  - 12 (17) Morphine-N-Oxide;
  - 13 (18) Myrophine;
  - 14 (19) Nicocodeine;
  - 15 (20) Nicomorphine;
  - 16 (21) Normorphine;
  - 17 (22) Pholcodine; and
  - 18 (23) Thebacon.
- 19 (c) Any material, compound, mixture, or preparation which  
20 contains any quantity of the following hallucinogenic substances,  
21 their salts, isomers, and salts of isomers, unless specifically  
22 excepted, whenever the existence of such salts, isomers, and salts  
23 of isomers is possible within the specific chemical designation,  
24 and, for purposes of this subdivision only, isomer shall include  
25 the optical, position, and geometric isomers:
- 26 (1) Bufotenine. Trade and other names shall include, but  
27 are not limited to: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole;

1 3-(2-dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin;  
2 5-hydroxy-N,N-dimethyltryptamine; and mappine;

3 (2) Diethyltryptamine. Trade and other names shall  
4 include, but are not limited to: N,N-Diethyltryptamine; and DET;

5 (3) Dimethyltryptamine. Trade and other names shall  
6 include, but are not limited to: DMT;

7 (4) 4-bromo-2,5-dimethoxyamphetamine. Trade  
8 and other names shall include, but are not limited  
9 to: 4-bromo-2,5-dimethoxy-alpha-methylphenethylamine; and  
10 4-bromo-2,5-DMA;

11 (5) 4-methoxyamphetamine. Trade and other  
12 names shall include, but are not limited to:  
13 4-methoxy-alpha-methylphenethylamine; and paramethoxyamphetamine,  
14 PMA;

15 (6) 4-methyl-2,5-dimethoxyamphetamine. Trade and  
16 other names shall include, but are not limited to:  
17 4-methyl-2,5-dimethoxy-alpha-methylphenethylamine; DOM; and STP;

18 (7) 5-methoxy-N,N-dimethyltryptamine;

19 (8) Ibogaine. Trade and other names  
20 shall include, but are not limited to:

21 7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido  
22 (1',2':1,2) azepino (5,4-b) indole; and Tabernanthe iboga;

23 (9) Lysergic acid diethylamide;

24 (10) Marijuana;

25 (11) Mescaline;

26 (12) Peyote. Peyote shall mean all parts of the plant  
27 presently classified botanically as *Lophophora williamsii* Lemaire,

1 whether growing or not, the seeds thereof, any extract from  
2 any part of such plant, and every compound, manufacture, salts,  
3 derivative, mixture, or preparation of such plant or its seeds or  
4 extracts;

5 (13) Psilocybin;

6 (14) Psilocyn;

7 (15) Tetrahydrocannabinols, including, but not limited  
8 to, synthetic equivalents of the substances contained in the plant  
9 or in the resinous extractives of cannabis, sp. or synthetic  
10 substances, derivatives, and their isomers with similar chemical  
11 structure and pharmacological activity such as the following: Delta  
12 1 cis or trans tetrahydrocannabinol and their optical isomers,  
13 excluding dronabinol in sesame oil and encapsulated in a soft  
14 gelatin capsule in a drug product approved by the federal Food  
15 and Drug Administration; Delta 6 cis or trans tetrahydrocannabinol  
16 and their optical isomers; and Delta 3,4 cis or trans  
17 tetrahydrocannabinol and its optical isomers. Since nomenclature  
18 of these substances is not internationally standardized, compounds  
19 of these structures shall be included regardless of the numerical  
20 designation of atomic positions covered;

21 (16) 3,4-methylenedioxy amphetamine;

22 (17) 5-methoxy-3,4-methylenedioxy-amphetamine;

23 (18) 3,4,5-trimethoxy amphetamine;

24 (19) N-ethyl-3-piperidyl benzilate;

25 (20) N-methyl-3-piperidyl benzilate;

26 (21) Thiophene analog of phencyclidine. Trade  
27 and other names shall include, but are not limited to:

1 1-(1-(2-thienyl)-cyclohexyl)-piperidine; 2-thienyl analog of  
2 phencyclidine; TPCP; and TCP;

3 (22) 2,5-dimethoxyamphetamine. Trade and  
4 other names shall include, but are not limited to:  
5 2,5-dimethoxy-alpha-methylphenethylamine; and 2,5-DMA;

6 (23) Hashish or concentrated cannabis;

7 (24) Parahexyl. Trade and other  
8 names shall include, but are not limited to:  
9 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo(b,d)pyran;  
10 and Synhexyl;

11 (25) Ethylamine analog of phencyclidine. Trade  
12 and other names shall include, but are not limited to:  
13 N-ethyl-1-phenylcyclohexylamine; (1-phenylcyclohexyl)ethylamine;  
14 N-(1-phenylcyclohexyl)ethylamine; cyclohexamine; and PCE;

15 (26) Pyrrolidine analog of phencyclidine. Trade  
16 and other names shall include, but are not limited to:  
17 1-(1-phenylcyclohexyl)-pyrrolidine; PCPy; and PHP;

18 (27) 3,4-methylenedioxymethamphetamine (MDMA), its  
19 optical, positional, and geometric isomers, salts, and salts of  
20 isomers;

21 (28) 4-Bromo-2,5-dimethoxyphenethylamine. Some trade  
22 or other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane;  
23 alpha-desmethyl DOB; 2C-B; and Nexus;

24 (29) Alpha-ethyltryptamine. Some trade or other  
25 names: etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine;  
26 3-(2-aminobutyl) indole; alpha-ET; and AET;

27 (30) 2,5-dimethoxy-4-ethylamphet-amine; and DOET;



1 (31) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; and TCPy;

2 (32) Alpha-methyltryptamine, which is also known as AMT;

3 (33) 5-Methoxy-N,N-diisopropyltryptamine, which is also  
4 known as 5-MeO-DIPT;

5 (34) Salvia divinorum or Salvinorin A. Salvia divinorum  
6 or Salvinorin A includes all parts of the plant presently  
7 classified botanically as Salvia divinorum, whether growing or not,  
8 the seeds thereof, any extract from any part of such plant, and  
9 every compound, manufacture, derivative, mixture, or preparation of  
10 such plant, its seeds, or its extracts, including salts, isomers,  
11 and salts of isomers whenever the existence of such salts, isomers,  
12 and salts of isomers is possible within the specific chemical  
13 designation; and

14 (35) Any material, compound, mixture, or preparation  
15 containing any quantity of synthetically produced cannabinoids as  
16 listed in subdivisions (i) through (viii) of this subdivision,  
17 including their salts, isomers, and salts of isomers, unless  
18 specifically excepted elsewhere in this section. Since nomenclature  
19 of these synthetically produced cannabinoids is not internationally  
20 standardized and may continually evolve, these structures or  
21 compounds of these structures shall be included under this  
22 subdivision, regardless of their specific numerical designation  
23 of atomic positions covered, so long as it can be determined  
24 through some form of scientific testing or analysis that the  
25 substance contains properties that fit within one or more of the  
26 following categories:

27 (i) Tetrahydrocannabinols: Meaning tetrahydrocannabinols

1 naturally contained in a plant of the genus cannabis (cannabis  
2 plant), as well as synthetic equivalents of the substances  
3 contained in the plant, or in the resinous extractives of  
4 cannabis, sp. and/or synthetic substances, derivatives, and  
5 their isomers with similar chemical structure and pharmacological  
6 activity such as the following: Delta 1 cis or trans  
7 tetrahydrocannabinol, and their optical isomers Delta 6 cis or  
8 trans tetrahydrocannabinol, and their optical isomers Delta 3,4 cis  
9 or trans tetrahydrocannabinol, and its optical isomers;

10 (ii) Naphthoylindoles: Any compound containing a  
11 3-(1-naphthoyl)indole structure with substitution at the nitrogen  
12 atom of the indole ring by a alkyl, haloalkyl, alkenyl,  
13 cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group,  
14 whether or not further substituted in the indole ring to any extent  
15 and whether or not substituted in the naphthyl ring to any extent;

16 (iii) Naphthylmethylinindoles: Any compound containing a 1  
17 H-indol-3-yl-(1-naphthyl)methane structure with substitution at the  
18 nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl,  
19 cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group,  
20 whether or not further substituted in the indole ring to any extent  
21 and whether or not substituted in the naphthyl ring to any extent;

22 (iv) Naphthoylpyrroles: Any compound containing a  
23 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen  
24 atom of the pyrrole ring by a alkyl, haloalkyl, alkenyl,  
25 cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group,  
26 whether or not further substituted in the pyrrole ring to any  
27 extent and whether or not substituted in the naphthyl ring to any

1 extent;

2 (v) Naphthylideneindenes: Any compound containing  
3 a naphthylideneindene structure with substitution at the  
4 3-position of the indene ring by a alkyl, haloalkyl, alkenyl,  
5 cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group,  
6 whether or not further substituted in the indene ring to any extent  
7 and whether or not substituted in the naphthyl ring to any extent;

8 (vi) Phenylacetylindoles: Any compound containing a  
9 3-phenylacetylindole structure with substitution at the nitrogen  
10 atom of the indole ring by a alkyl, haloalkyl, alkenyl,  
11 cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group,  
12 whether or not further substituted in the indole ring to any extent  
13 and whether or not substituted in the phenyl ring to any extent;

14 (vii) Cyclohexylphenols: Any compound containing a  
15 2-(3-hydroxycyclohexyl)phenol structure with substitution at the  
16 5-position of the phenolic ring by a alkyl, haloalkyl, alkenyl,  
17 cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group,  
18 whether or not substituted in the cyclohexyl ring to any extent;  
19 and

20 (viii) Benzoylindoles: Any compound containing a  
21 3-(benzoyl)indole structure with substitution at the nitrogen  
22 atom of the indole ring by a alkyl, haloalkyl, alkenyl,  
23 cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group,  
24 whether or not further substituted in the indole ring to any extent  
25 and whether or not substituted in the phenyl ring to any extent;

26 and-

27 (36) (A) Any substance containing any quantity of the

1 following materials, compounds, mixtures, or structures:

2 (i) 3,4-methylenedioxy methcathinone, or bk-MDMA, or  
3 methylone;

4 (ii) 3,4-methylenedioxy pyrovalerone, or MDPV;

5 (iii) 4-methylmethcathinone, or 4-MMC, or mephedrone;

6 (iv) 4-methoxymethcathinone, or bk-PMMA, or PMMC, or  
7 methedrone;

8 (v) Fluoromethcathinone, or FMC;

9 (vi) Napthylpyrovalerone, or naphyrone; or

10 (vii) Beta-keto-N-methylbenzodioxolylpropylamine; or

11 (B) Unless listed in another schedule, any substance  
12 which contains any quantity of any material, compound, mixture,  
13 or structure, other than bupropion, that is structurally derived  
14 by any means from 2-aminopropan-1-one by substitution at the  
15 1-position with either phenyl, naphthyl, or thiophene ring systems,  
16 whether or not the compound is further modified in any of the  
17 following ways:

18 (i) Substitution in the ring system to any extent  
19 with alkyl, alkoxy, alkylendioxy, haloalkyl, hydroxyl, or halide  
20 substituents, whether or not further substituted in the ring system  
21 by one or more other univalent substituents;

22 (ii) Substitution at the 3-position with an acyclic alkyl  
23 substituent; or

24 (iii) Substitution at the 2-amino nitrogen atom with  
25 alkyl or dialkyl groups, or by inclusion of the 2-amino nitrogen  
26 atom in a cyclic structure.

27 (d) Unless specifically excepted or unless listed in

1 another schedule, any material, compound, mixture, or preparation  
2 which contains any quantity of the following substances having  
3 a depressant effect on the central nervous system, including its  
4 salts, isomers, and salts of isomers whenever the existence of  
5 such salts, isomers, and salts of isomers is possible within the  
6 specific chemical designation:

- 7 (1) Mecloqualone;
- 8 (2) Methaqualone; and
- 9 (3) Gamma-Hydroxybutyric Acid. Some other names include:  
10 GHB; Gamma-hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic  
11 Acid; Sodium Oxybate; and Sodium Oxybutyrate.

12 (e) Unless specifically excepted or unless listed in  
13 another schedule, any material, compound, mixture, or preparation  
14 which contains any quantity of the following substances having  
15 a stimulant effect on the central nervous system, including its  
16 salts, isomers, and salts of isomers:

- 17 (1) Fenethylamine;
- 18 (2) N-ethylamphetamine;
- 19 (3) Aminorex; aminoxaphen; 2-amino-5-phenyl-2-oxazoline;  
20 or 4,5-dihydro-5-phenyl-2-oxazolamine;
- 21 (4) Cathinone; 2-amino-1-phenyl-1-propanone;  
22 alpha-aminopropiophenone; 2-aminopropiophenone; and norephedrine;
- 23 (5) Methcathinone, its salts, optical isomers,  
24 and salts of optical isomers. Some other names:  
25 2-(methylamino)-propionophenone; alpha-(methylamino)propionophenone;  
26 2-(methylamino)-1-phenylpropan-1-one;  
27 alpha-N-methylaminopropiophenone; methylcathinone;

1 monomethylpropion; ephedrone; N-methylcathinone; AL-464; AL-422;  
2 AL-463; and UR1432;

3 (6) (+/-) cis-4-methylaminorex; and  
4 (+/-) cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine;

5 (7) N,N-dimethylamphetamine;  
6 N,N-alpha-trimethyl-benzeneethanamine; and  
7 N,N-alpha-trimethylphenethylamine; and

8 (8) Benzylpiperazine, 1-benzylpiperazine.

9 (f) Any controlled substance analogue to the extent  
10 intended for human consumption.

11 Schedule II

12 (a) Any of the following substances except those narcotic  
13 drugs listed in other schedules whether produced directly or  
14 indirectly by extraction from substances of vegetable origin,  
15 independently by means of chemical synthesis, or by combination of  
16 extraction and chemical synthesis:

17 (1) Opium and opiate, and any salt, compound, derivative,  
18 or preparation of opium or opiate, excluding apomorphine,  
19 buprenorphine, thebaine-derived butorphanol, dextrorphan,  
20 nalbuphine, nalmefene, naloxone, and naltrexone and their  
21 salts, but including the following:

- 22 (i) Raw opium;
- 23 (ii) Opium extracts;
- 24 (iii) Opium fluid;
- 25 (iv) Powdered opium;
- 26 (v) Granulated opium;
- 27 (vi) Tincture of opium;

- 1                   (vii) Codeine;
- 2                   (viii) Ethylmorphine;
- 3                   (ix) Etorphine hydrochloride;
- 4                   (x) Hydrocodone;
- 5                   (xi) Hydromorphone;
- 6                   (xii) Metopon;
- 7                   (xiii) Morphine;
- 8                   (xiv) Oxycodone;
- 9                   (xv) Oxymorphone;
- 10                  (xvi) Oripavine;
- 11                  (xvii) Thebaine; and
- 12                  (xviii) Dihydroetorphine;
- 13                  (2) Any salt, compound, derivative, or preparation
- 14 thereof which is chemically equivalent to or identical with any of
- 15 the substances referred to in subdivision (1) of this subdivision,
- 16 except that these substances shall not include the isoquinoline
- 17 alkaloids of opium;
- 18                  (3) Opium poppy and poppy straw;
- 19                  (4) Coca leaves and any salt, compound, derivative, or
- 20 preparation of coca leaves, and any salt, compound, derivative,
- 21 or preparation thereof which is chemically equivalent to or
- 22 identical with any of these substances, including cocaine and
- 23 its salts, optical isomers, and salts of optical isomers, except
- 24 that the substances shall not include decocainized coca leaves or
- 25 extractions which do not contain cocaine or ecgonine; and
- 26                  (5) Concentrate of poppy straw, the crude extract of
- 27 poppy straw in either liquid, solid, or powder form which contains

1 the phenanthrene alkaloids of the opium poppy.

2 (b) Unless specifically excepted or unless in another  
3 schedule any of the following opiates, including their isomers,  
4 esters, ethers, salts, and salts of their isomers, esters, and  
5 ethers whenever the existence of such isomers, esters, ethers,  
6 and salts is possible within the specific chemical designation,  
7 dextrorphan excepted:

8 (1) Alphaprodine;

9 (2) Anileridine;

10 (3) Bezitramide;

11 (4) Diphenoxylate;

12 (5) Fentanyl;

13 (6) Isomethadone;

14 (7) Levomethorphan;

15 (8) Levorphanol;

16 (9) Metazocine;

17 (10) Methadone;

18 (11) Methadone-intermediate,  
19 4-cyano-2-dimethylamino-4,4-diphenyl butane;

20 (12) Moramide-intermediate,  
21 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid;

22 (13) Pethidine or meperidine;

23 (14) Pethidine-Intermediate-A,  
24 4-cyano-1-methyl-4-phenylpiperidine;

25 (15) Pethidine-Intermediate-B,  
26 ethyl-4-phenylpiperidine-4-carboxylate;

27 (16) Pethidine-Intermediate-C,



1 1-methyl-4-phenylpiperidine-4-carboxylic acid;

2 (17) Phenazocine;

3 (18) Piminodine;

4 (19) Racemethorphan;

5 (20) Racemorphan;

6 (21) Dihydrocodeine;

7 (22) Bulk Propoxyphene in nondosage forms;

8 (23) Sufentanil;

9 (24) Alfentanil;

10 (25) Levo-alpha-acetylmethadol which is also known as

11 levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;

12 (26) Carfentanil;

13 (27) Remifentanil; and

14 (28) Tapentadol.

15 (c) Any material, compound, mixture, or preparation  
16 which contains any quantity of the following substances having  
17 a potential for abuse associated with a stimulant effect on the  
18 central nervous system:

19 (1) Amphetamine, its salts, optical isomers, and salts of  
20 its optical isomers;

21 (2) Phenmetrazine and its salts;

22 (3) Methamphetamine, its salts, isomers, and salts of its  
23 isomers; and

24 (4) Methylphenidate.

25 (d) Any material, compound, mixture, or preparation  
26 which contains any quantity of the following substances having  
27 a potential for abuse associated with a depressant effect on the

1 central nervous system, including their salts, isomers, and salts  
2 of isomers whenever the existence of such salts, isomers, and salts  
3 of isomers is possible within the specific chemical designations:

- 4 (1) Amobarbital;
- 5 (2) Secobarbital;
- 6 (3) Pentobarbital;
- 7 (4) Phencyclidine; and
- 8 (5) Glutethimide.

9 (e) Hallucinogenic substances known as:

- 10 (1) Nabilone. Another name for  
11 nabilone: (+/-)-trans-3-(1,1-dimethylheptyl)-  
12 6,6a,7,8,10,10a-Hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo(b,d)pyran-9-one.

13 (f) Unless specifically excepted or unless listed in  
14 another schedule, any material, compound, mixture, or preparation  
15 which contains any quantity of the following substances:

- 16 (1) Immediate precursor to amphetamine and  
17 methamphetamine: Phenylacetone. Trade and other names shall  
18 include, but are not limited to: Phenyl-2-propanone; P2P; benzyl  
19 methyl ketone; and methyl benzyl ketone; or

20 (2) Immediate precursors to phencyclidine, PCP:

- 21 (i) 1-phenylcyclohexylamine; or
- 22 (ii) 1-piperidinocyclohexanecarbonitrile, PCC.

23 Schedule III

24 (a) Any material, compound, mixture, or preparation  
25 which contains any quantity of the following substances having  
26 a potential for abuse associated with a stimulant effect on the  
27 central nervous system, including their salts, isomers, whether

1 optical, position, or geometric, and salts of such isomers whenever  
2 the existence of such salts, isomers, and salts of isomers is  
3 possible within the specific chemical designation:

- 4 (1) Benzphetamine;
- 5 (2) Chlorphentermine;
- 6 (3) Clortermine; and
- 7 (4) Phendimetrazine.

8 (b) Any material, compound, mixture, or preparation  
9 which contains any quantity of the following substances having  
10 a potential for abuse associated with a depressant effect on the  
11 central nervous system:

12 (1) Any substance which contains any quantity of a  
13 derivative of barbituric acid or any salt of a derivative of  
14 barbituric acid, except those substances which are specifically  
15 listed in other schedules of this section;

- 16 (2) Chlorhexadol;
- 17 (3) Lysergic acid;
- 18 (4) Lysergic acid amide;
- 19 (5) Methyprylon;
- 20 (6) Sulfondiethylmethane;
- 21 (7) Sulfonethylmethane;
- 22 (8) Sulfonmethane;
- 23 (9) Nalorphine;

24 (10) Any compound, mixture, or preparation containing  
25 amobarbital, secobarbital, pentobarbital, or any salt thereof and  
26 one or more other active medicinal ingredients which are not listed  
27 in any schedule;

1           (11) Any suppository dosage form containing amobarbital,  
2           secobarbital, pentobarbital, or any salt of any of these drugs and  
3           approved by the Food and Drug Administration for marketing only as  
4           a suppository;

5           (12) Any drug product containing gamma-hydroxybutyric  
6           acid, including its salts, isomers, and salts of isomers, for which  
7           an application is approved under section 505 of the Federal Food,  
8           Drug, and Cosmetic Act, 21 U.S.C. 355, as such section existed on  
9           July 20, 2002;

10           (13) Ketamine, its salts, isomers, and  
11           salts of isomers. Some other names for ketamine:  
12           (+/-)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone; and

13           (14) Tiletamine and zolazepam or any salt thereof.  
14           Trade or other names for a tiletamine-zolazepam combination  
15           product shall include, but are not limited to: telazol. Trade  
16           or other names for tiletamine shall include, but are not  
17           limited to: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone. Trade or  
18           other names for zolazepam shall include, but are not limited  
19           to: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-(3,4-e)  
20           (1,4)-diazepin-7(1H)-one, and flupyrzapon.

21           (c) Unless specifically excepted or unless listed in  
22           another schedule:

23           (1) Any material, compound, mixture, or preparation  
24           containing limited quantities of any of the following narcotic  
25           drugs, or any salts calculated as the free anhydrous base or  
26           alkaloid, in limited quantities as set forth below:

27           (i) Not more than one and eight-tenths grams of codeine

1 per one hundred milliliters or not more than ninety milligrams per  
2 dosage unit, with an equal or greater quantity of an isoquinoline  
3 alkaloid of opium;

4 (ii) Not more than one and eight-tenths grams of codeine  
5 per one hundred milliliters or not more than ninety milligrams per  
6 dosage unit, with one or more active, nonnarcotic ingredients in  
7 recognized therapeutic amounts;

8 (iii) Not more than three hundred milligrams of  
9 dihydrocodeinone which is also known as hydrocodone per one hundred  
10 milliliters or not more than fifteen milligrams per dosage unit,  
11 with a fourfold or greater quantity of an isoquinoline alkaloid of  
12 opium;

13 (iv) Not more than three hundred milligrams of  
14 dihydrocodeinone which is also known as hydrocodone per one hundred  
15 milliliters or not more than fifteen milligrams per dosage unit,  
16 with one or more active, nonnarcotic ingredients in recognized  
17 therapeutic amounts;

18 (v) Not more than one and eight-tenths grams of  
19 dihydrocodeine per one hundred milliliters or not more than ninety  
20 milligrams per dosage unit, with one or more active, nonnarcotic  
21 ingredients in recognized therapeutic amounts;

22 (vi) Not more than three hundred milligrams of  
23 ethylmorphine per one hundred milliliters or not more than fifteen  
24 milligrams per dosage unit, with one or more active, nonnarcotic  
25 ingredients in recognized therapeutic amounts;

26 (vii) Not more than five hundred milligrams of opium per  
27 one hundred milliliters or per one hundred grams, or not more than

1 twenty-five milligrams per dosage unit, with one or more active,  
2 nonnarcotic ingredients in recognized therapeutic amounts; and

3 (viii) Not more than fifty milligrams of morphine per  
4 one hundred milliliters or per one hundred grams with one or more  
5 active, nonnarcotic ingredients in recognized therapeutic amounts;  
6 and

7 (2) Any material, compound, mixture, or preparation  
8 containing any of the following narcotic drug or its salts, as  
9 set forth below:

10 (i) Buprenorphine.

11 (d) Unless contained on the administration's list of  
12 exempt anabolic steroids as the list existed on June 1, 2007,  
13 any anabolic steroid, which shall include any material, compound,  
14 mixture, or preparation containing any quantity of the following  
15 substances, including its salts, isomers, and salts of isomers  
16 whenever the existence of such salts of isomers is possible within  
17 the specific chemical designation:

18 (1) Boldenone;

19 (2) Boldione;

20 (3) Chlorotestosterone (4-chlorotestosterone);

21 (4) Clostebol;

22 (5) Dehydrochloromethyltestosterone;

23 (6) Desoxymethyltestosterone;

24 (7) Dihydrotestosterone (4-dihydrotestosterone);

25 (8) Drostanolone;

26 (9) Ethylestrenol;

27 (10) Fluoxymesterone;

- 1 (11) Formebolone (formebolone);
- 2 (12) Mesterolone;
- 3 (13) Methandienone;
- 4 (14) Methandranone;
- 5 (15) Methandriol;
- 6 (16) Methandrostenolone;
- 7 (17) Methenolone;
- 8 (18) Methyltestosterone;
- 9 (19) Mibolerone;
- 10 (20) Nandrolone;
- 11 (21) Norethandrolone;
- 12 (22) Oxandrolone;
- 13 (23) Oxymesterone;
- 14 (24) Oxymetholone;
- 15 (25) Stanolone;
- 16 (26) Stanozolol;
- 17 (27) Testolactone;
- 18 (28) Testosterone;
- 19 (29) Trenbolone;
- 20 (30) 19-nor-4,9(10)-androstadienedione; and
- 21 (31) Any salt, ester, or ether of a drug or substance
- 22 described or listed in this subdivision if the salt, ester, or
- 23 ether promotes muscle growth.

24 (e) Hallucinogenic substances known as:

- 25 (1) Dronabinol, synthetic, in sesame oil and encapsulated
- 26 in a soft gelatin capsule in a Food and Drug Administration
- 27 approved drug product. Some other names for dronabinol are

1 (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo  
2 (b,d)pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol.

3 Schedule IV

4 (a) Any material, compound, mixture, or preparation which  
5 contains any quantity of the following substances, including their  
6 salts, isomers, and salts of isomers whenever the existence of  
7 such salts, isomers, and salts of isomers is possible within the  
8 specific chemical designation:

- 9 (1) Barbital;
- 10 (2) Chloral betaine;
- 11 (3) Chloral hydrate;
- 12 (4) Chlordiazepoxide, but not including librax  
13 (chlordiazepoxide hydrochloride and clindinium bromide) or menrium  
14 (chlordiazepoxide and water soluble esterified estrogens);
- 15 (5) Clonazepam;
- 16 (6) Clorazepate;
- 17 (7) Diazepam;
- 18 (8) Ethchlorvynol;
- 19 (9) Ethinamate;
- 20 (10) Flurazepam;
- 21 (11) Mebutamate;
- 22 (12) Meprobamate;
- 23 (13) Methohexital;
- 24 (14) Methylphenobarbital;
- 25 (15) Oxazepam;
- 26 (16) Paraldehyde;
- 27 (17) Petrichloral;



- 1 (18) Phenobarbital;
- 2 (19) Prazepam;
- 3 (20) Alprazolam;
- 4 (21) Bromazepam;
- 5 (22) Camazepam;
- 6 (23) Clobazam;
- 7 (24) Clotiazepam;
- 8 (25) Cloxazolam;
- 9 (26) Delorazepam;
- 10 (27) Estazolam;
- 11 (28) Ethyl loflazepate;
- 12 (29) Fludiazepam;
- 13 (30) Flunitrazepam;
- 14 (31) Halazepam;
- 15 (32) Haloxazolam;
- 16 (33) Ketazolam;
- 17 (34) Loprazolam;
- 18 (35) Lorazepam;
- 19 (36) Lormetazepam;
- 20 (37) Medazepam;
- 21 (38) Nimetazepam;
- 22 (39) Nitrazepam;
- 23 (40) Nordiazepam;
- 24 (41) Oxazolam;
- 25 (42) Pinazepam;
- 26 (43) Temazepam;
- 27 (44) Tetrazepam;

- 1 (45) Triazolam;
- 2 (46) Midazolam;
- 3 (47) Quazepam;
- 4 (48) Zolpidem;
- 5 (49) Dichloralphenazone; and
- 6 (50) Zaleplon.

7 (b) Any material, compound, mixture, or preparation which  
8 contains any quantity of the following substance, including its  
9 salts, isomers, whether optical, position, or geometric, and salts  
10 of such isomers, whenever the existence of such salts, isomers, and  
11 salts of isomers is possible: Fenfluramine.

12 (c) Unless specifically excepted or unless listed in  
13 another schedule, any material, compound, mixture, or preparation  
14 which contains any quantity of the following substances having a  
15 stimulant effect on the central nervous system, including their  
16 salts, isomers, whether optical, position, or geometric, and salts  
17 of such isomers whenever the existence of such salts, isomers,  
18 and salts of isomers is possible within the specific chemical  
19 designation:

- 20 (1) Diethylpropion;
- 21 (2) Phentermine;
- 22 (3) Pemoline, including organometallic complexes and  
23 chelates thereof;
- 24 (4) Mazindol;
- 25 (5) Pipradrol;
- 26 (6) SPA, ((-)-1-dimethylamino- 1,2-diphenylethane);
- 27 (7) Cathine. Another name for cathine is

1 ((+)-norpseudoephedrine);

2 (8) Fencamfamin;

3 (9) Fenproporex;

4 (10) Mefenorex;

5 (11) Modafinil; and

6 (12) Sibutramine.

7 (d) Unless specifically excepted or unless listed in  
8 another schedule, any material, compound, mixture, or preparation  
9 which contains any quantity of the following narcotic drugs, or  
10 their salts or isomers calculated as the free anhydrous base or  
11 alkaloid, in limited quantities as set forth below:

12 (1) Propoxyphene in manufactured dosage forms; and

13 (2) Not more than one milligram of difenoxin and not less  
14 than twenty-five micrograms of atropine sulfate per dosage unit.

15 (e) Unless specifically excepted or unless listed in  
16 another schedule, any material, compound, mixture, or preparation  
17 which contains any quantity of the following substance, including  
18 its salts: Pentazocine.

19 (f) Unless specifically excepted or unless listed in  
20 another schedule, any material, compound, mixture, or preparation  
21 which contains any quantity of the following substance, including  
22 its salts, isomers, and salts of such isomers: Butorphanol.

23 (g) Unless specifically excepted or unless listed in  
24 another schedule, any material, compound, mixture, or preparation  
25 which contains any quantity of the following substance, including  
26 its salts, isomers, and salts of such isomers: Carisoprodol.

27 ~~(g) (1)~~ (h) (1) Unless specifically excepted or unless

1 listed in another schedule, any material, compound, mixture, or  
2 preparation which contains any quantity of the following substance,  
3 including its salts, optical isomers, and salts of such optical  
4 isomers: Ephedrine.

5 (2) The following drug products containing ephedrine, its  
6 salts, optical isomers, and salts of such optical isomers, are  
7 excepted from subdivision ~~(g)(1)~~ (h)(1) of Schedule IV if they  
8 (A) are stored behind a counter, in an area not accessible to  
9 customers, or in a locked case so that a customer needs assistance  
10 from an employee to access the drug product; (B) are sold by a  
11 person, eighteen years of age or older, in the course of his or her  
12 employment to a customer eighteen years of age or older with the  
13 following restrictions: No customer shall be allowed to purchase,  
14 receive, or otherwise acquire more than three and six-tenths grams  
15 of ephedrine base during a twenty-four-hour period; no customer  
16 shall purchase, receive, or otherwise acquire more than nine grams  
17 of ephedrine base during a thirty-day period; and the customer  
18 shall display a valid driver's or operator's license, a Nebraska  
19 state identification card, a military identification card, an alien  
20 registration card, or a passport as proof of identification; (C)  
21 are labeled and marketed in a manner consistent with the pertinent  
22 OTC Tentative Final or Final Monograph; (D) are manufactured and  
23 distributed for legitimate medicinal use in a manner that reduces  
24 or eliminates the likelihood of abuse; and (E) are not marketed,  
25 advertised, or represented in any manner for the indication of  
26 stimulation, mental alertness, euphoria, ecstasy, a buzz or high,  
27 heightened sexual performance, or increased muscle mass:

- 1 (i) Primatene Tablets; and  
2 (ii) Bronkaid Dual Action Caplets; ~~and~~  
3 ~~(iii) Paze Hemorrhoidal Ointment.~~

4 Schedule V

5 (a) Any compound, mixture, or preparation containing any  
6 of the following limited quantities of narcotic drugs or salts  
7 calculated as the free anhydrous base or alkaloid, which shall  
8 include one or more nonnarcotic active medicinal ingredients in  
9 sufficient proportion to confer upon the compound, mixture, or  
10 preparation valuable medicinal qualities other than those possessed  
11 by the narcotic drug alone:

12 (1) Not more than two hundred milligrams of codeine per  
13 one hundred milliliters or per one hundred grams;

14 (2) Not more than one hundred milligrams of  
15 dihydrocodeine per one hundred milliliters or per one hundred  
16 grams;

17 (3) Not more than one hundred milligrams of ethylmorphine  
18 per one hundred milliliters or per one hundred grams;

19 (4) Not more than two and five-tenths milligrams of  
20 diphenoxylate and not less than twenty-five micrograms of atropine  
21 sulfate per dosage unit;

22 (5) Not more than one hundred milligrams of opium per one  
23 hundred milliliters or per one hundred grams; and

24 (6) Not more than five-tenths milligram of difenoxin and  
25 not less than twenty-five micrograms of atropine sulfate per dosage  
26 unit.

27 (b) Unless specifically exempted or excluded or unless

1 listed in another schedule, any material, compound, mixture, or  
2 preparation which contains any quantity of the following substances  
3 having a stimulant effect on the central nervous system, including  
4 its salts, isomers, and salts of isomers: Pyrovalerone.

5 (c) Unless specifically exempted or excluded or unless  
6 listed in another schedule, any material, compound, mixture, or  
7 preparation which contains any quantity of the following substances  
8 having a depressant effect on the central nervous system, including  
9 its salts, isomers, and salts of isomers:

10 (1) Ezogabine  
11 [N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic  
12 acid ethyl ester];

13 (2) Lacosamide  
14 [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide]; and

15 (3) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic  
16 acid].

17 Sec. 2. Original section 28-405, Revised Statutes  
18 Supplement, 2011, is repealed.

19 Sec. 3. Since an emergency exists, this act takes effect  
20 when passed and approved according to law.